Repurposing of Inhibitors of Plasmodial Aspartate Transcarbamoylase Toward Trypanosoma Cruzi
ChemMedChem · 27.03.2026 · 21 (6)
DOI: 10.1002/cmdc.202500817 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 26.03.2026. Verfasst von Siyao Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Pharmaceutical Biology, University of Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Trypanosoma cruzi, Aspartate Carbamoyltransferase, Enzyme Inhibitors, Drug Repositioning. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H2020 Marie Skłodowska-Curie Actions, China Sponsorship Council.
Abstract (Originalsprache)
Aspartate transcarbamoylase (ATC) catalyzes the committed and rate‐limiting step in the pyrimidine de novo biosynthesis pathway. While previously suggested to be a potential target for antimalarial, antitubercular, and antioncologic drug discovery, we hypothesized that an existing compound library of ATC inhibitors designed from one scaffold by fragment screening against Plamodium falciparum ATC ( Pf ATC) may also contain inhibitors of Trypanosoma cruzi ATC ( Tc ATC). In this manuscript, we screened the 70‐member library at 35 μM against 50 nM Tc ATC, and in these initial experiments, 34 compounds showed over 90% inhibition. Of the 34 compounds, 5 compounds demonstrated IC 50 values of lower than 250 nM in a follow‐up enzymatic half inhibition concentration analysis. Kinetic studies on one of these compounds indicate that they inhibit Tc ATC in a noncompetitive manner, and a druggable allosteric pocket is seen in the available crystal structure. While cocrystallization and soaking experiments were unsuccessful, molecular modeling was performed to assess potential binding modes. Two of the best‐performing compounds were selected for a cellular assay, showing EC 50 s of 7.4 µM and 6.5 µM. However, significant cotoxicity was also observed, demonstrating that further elaboration of the compounds is necessary. These results suggest that this compound library might be a starting point for antitrypanosomatid drug discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical and Pharmaceutical Biology, University of Groningen, Groningen, The Netherlands.
- Department Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
- University of Basel, Basel, Switzerland.
- Unit in Bioinformatics (RUBi), Department of Biochemistry, Microbiology and Biochemistry, Rhodes University, Makhanda, South Africa.
- Innovative Chemistry Group, Institute for Molecular and Translational Medicine (IMTM) and Czech Advanced Technology and Research Institute (CATRIN) Univerzita Palackého v Olomouci, Olomouc, Czechia.
- National Institute for Theoretical and Computational Studies (NITheCS), Stellenbosch, South Africa.
ORCID-Profile: Matthew R Groves
Förderung
- H2020 Marie Skłodowska-Curie Actions
- China Sponsorship Council
Zitieren
APA
Chen, S., Cal, M., Mondile, Q., Oerlemans, R., Shashikant, M. M., Dömling, A. S. S., Bishop, Ö. T., Mäser, P., & Groves, M. R. (2026). Repurposing of Inhibitors of Plasmodial Aspartate Transcarbamoylase Toward Trypanosoma Cruzi. ChemMedChem, 21(6). https://doi.org/10.1002/cmdc.202500817
Vancouver
Chen S, Cal M, Mondile Q, Oerlemans R, Shashikant MM, Dömling ASS, et al. Repurposing of Inhibitors of Plasmodial Aspartate Transcarbamoylase Toward Trypanosoma Cruzi. ChemMedChem. 2026;21(6). doi:10.1002/cmdc.202500817
BibTeX
@article{Chen2026,
author = {Chen, Siyao and Cal, Monica and Mondile, Queenie and Oerlemans, Rick and Shashikant, Mukim Mayur and Dömling, Alexander S S and Bishop, Özlem Tastan and Mäser, Pascal and Groves, Matthew R},
title = {Repurposing of Inhibitors of Plasmodial Aspartate Transcarbamoylase Toward Trypanosoma Cruzi},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {6},
doi = {10.1002/cmdc.202500817}
}
EUVIMED